| Lymphoma, Follicular
Gazyva vs Tazverik
Side-by-side clinical, coverage, and cost comparison for lymphoma, follicular.Deep comparison between: Gazyva vs Tazverik with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTazverik has a higher rate of injection site reactions vs Gazyva based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tazverik but not Gazyva, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Gazyva
Tazverik
At A Glance
IV infusion
Anti-CD20 monoclonal antibody
Oral
Twice daily
EZH2 methyltransferase inhibitor
Indications
- Chronic Lymphocytic Leukemia
- Lymphoma, Follicular
- Lupus Nephritis
- Sarcoma, Epithelioid
- Lymphoma, Follicular
Dosing
Chronic Lymphocytic Leukemia 100 mg IV on day 1 and 900 mg on day 2 of Cycle 1, then 1,000 mg on days 8 and 15 of Cycle 1, and 1,000 mg on day 1 of Cycles 2-6 (28-day cycles) in combination with chlorambucil.
Lymphoma, Follicular 1,000 mg IV on days 1, 8, and 15 of Cycle 1, then 1,000 mg on day 1 of Cycles 2-6 or 2-8 in combination with chemotherapy; responding patients continue on 1,000 mg monotherapy every 2 months for up to 2 years.
Lupus Nephritis 1,000 mg IV at initial infusion (Dose 1), at Week 2 (Dose 2), at Week 24 (Dose 3), at Week 26 (Dose 4), then 1,000 mg every 6 months thereafter, in combination with standard therapy.
Sarcoma, Epithelioid 800 mg orally twice daily with or without food until disease progression or unacceptable toxicity.
Lymphoma, Follicular 800 mg orally twice daily with or without food until disease progression or unacceptable toxicity; select patients based on EZH2 mutation of codons Y646, A682, or A692 for EZH2-mutant R/R FL.
Contraindications
- Known hypersensitivity reaction (e.g., anaphylaxis) to obinutuzumab or any excipient
- Serum sickness with prior obinutuzumab use
—
Adverse Reactions
Most common (>=10%) Infusion-related reactions, neutropenia, thrombocytopenia, diarrhea, fatigue, upper respiratory tract infection, musculoskeletal pain
Serious Hepatitis B virus reactivation, progressive multifocal leukoencephalopathy, infusion-related reactions, hypersensitivity reactions including serum sickness, tumor lysis syndrome, infections, neutropenia, thrombocytopenia, disseminated intravascular coagulation
Postmarketing Serum sickness
Most common (>=20%) - Sarcoma, Epithelioid pain, fatigue, nausea, decreased appetite, vomiting, constipation
Most common (>=20%) - Lymphoma, Follicular fatigue, upper respiratory tract infection, musculoskeletal pain, nausea, abdominal pain
Serious - Sarcoma, Epithelioid hemorrhage, pleural effusion, skin infection, dyspnea, pain, respiratory distress
Serious - Lymphoma, Follicular general physical health deterioration, abdominal pain, pneumonia, sepsis, anemia
Pharmacology
Obinutuzumab is a humanized anti-CD20 IgG1 monoclonal antibody with reduced fucose content that mediates B-cell lysis via immune effector cell engagement (ADCC and ADCP), direct intracellular death signaling, and complement activation; its reduced fucose content confers greater ADCC activity than rituximab.
Tazemetostat is a selective inhibitor of EZH2 methyltransferase and certain gain-of-function mutations (Y646X, A682G, A692V), blocking trimethylation of histone H3 lysine 27 and relieving transcriptional repression that drives tumor growth in epithelioid sarcoma (via SWI/SNF complex dysfunction) and B-cell lymphoma with or without EZH2 mutation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Gazyva
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (0/12)
Tazverik
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (3/12)
UnitedHealthcare
Gazyva
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Tazverik
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Gazyva
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (2/3)
Tazverik
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Chronic Lymphocytic Leukemia (CLL)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableCancerCare: Non-Hodgkin Lymphoma
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
GazyvaView full Gazyva profile
TazverikView full Tazverik profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.